Abstract:Jun Li, 1, &ast Yangyang Yang, 2, &ast Xiumin Han, 3, &ast Jing Li, 2 Mengxiao Tian, 1 Wenjing Qi, 1 Huniu An, 3 Chuanchuan Wu, 1 Yao Zhang, 1 Shuai Han, 4 Liping Duan, 4 Weisi Wang, 4 Wenbao Zhang 1 1 State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medical Research Institute, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People's Republic of China; 2 Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, People's Republic of China; 3 Qinghai Provincial People's Hospital, Xining, Qinghai, People's Republic of China; 4 NHC Key Laboratory of Parasite and Vector Biology, WHO Collaborating Centre for Tropical Diseases, National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenbao Zhang; Weisi Wang, Tel +86 991 4366319 ; +86 21 64377008, Email ; Background: Alveolar echinococcosis (AE) is a lethal parasitic disease caused by infection with the metacestode of the dog/fox tapeworm Echinococcus multilocularis , which primarily affects the liver. Although continued efforts have been made to find new drugs against this orphan and neglected disease, the current treatment options remain limited, with drug delivery considered a likely barrier for successful treatment. Methods: Nanoparticles (NPs) have gained much attention in the field of drug delivery due to their potential to improve delivery efficiency and targetability. In this study, biocompatible PLGA nanoparticles encapsulating a novel carbazole aminoalcohol anti-AE agent (H1402) were prepared to promote the delivery of the parent drug to liver tissue for treating hepatic AE. Results: H1402-loaded nanoparticles (H1402-NPs) had a uniform spherical shape and a mean particle size of 55 nm. Compound H1402 was efficiently encapsulated into PLGA NPs with a maximal encapsulation efficiency of 82.1% and drug loading content of 8.2%. An in vitro uptake assay demonstrated that H1402-NPs rapidly penetrated the in vitro cultured pre-cyst wall and extensively accumulated in the pre-cysts of E. multilocularis within only 1 h. The biodistribution profile of H1402-NPs determined through ex vivo fluorescence imaging revealed significantly enhanced liver distribution compared to unencapsulated H1402, which translated to improved therapeutic efficacy and reduced systemic toxicity (especially hepatotoxicity and cytotoxicity) in a hepatic AE murine model. Following a 30-day oral regimen (100 mg/kg/day), H1402-NPs significantly reduced the parasitic burden in both the parasite mass (liver and metacestode total weight, 8.8%) and average metacestode size (89.9%) compared to unmedicated infected mice (both p -values < 0.05); the treatment outcome was more effective than those of albendazole- and free H1402-treated individuals. Conclusion: Our findings demonstrate the advantages of encapsulating H1402 into PLGA nanoparticles and highlight the potential of H1402-NPs as a promising liver-targeting therapeutic strategy for hepatic AE. Graphical Keywords: alveolar echinococcosis, Echinococcus multilocularis , PLGA, nanoparticles, liver targeting, oral administration Graphical Human alveolar echinococcosis (AE) is a life-threatening parasitic disease caused by infection with the larval form (metacestode) of the dog/fox tapeworm Echinococcus multilocularis . Human AE is considered an orphan and neglected disease by the World Health Organization. AE is endemic in the northern hemisphere, especially in Eurasia. 1 The current estimate of the global burden of human AE is 687,823 disability-adjusted life years (DALYs). 2 Most cases of AE occur in China, with an estimated 34,000 cases during 2012–2016. 3 A total of 115 counties in China are considered to be AE-endemic, and are predominantly distributed in the Qinghai-Tibetan Plateau, with a human prevalence of ≥ 5% in some local communities. 1,3–5 In Europe, AE is the top-ranked foodborne parasitic disease and shows an increasing trend in human incidence in some previously recognized endemic areas, despite the relatively small case numbers reported. 2,6,7 The natural life cycle of E. multilocularis typically involves canids (mostly foxes and dogs) as definitive hosts and small mammals (often rod -Abstract Truncated-

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms

Immunoprotective Effect and Mechanism of Reg.p29 Against CD4+ T Cell-Deficient Mice with Echinococcus Multilocularis Infection

Therapeutic effect on Alveolar echinococcosis by targeting EM-Leucine aminopeptidase

In Vitro and in Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis

Suppressive effect of pseudolaric acid B on Echinococcus multilocularis involving regulation of TGF-β1 signaling in vitro and in vivo

Synergism Therapeutic and Immunoregulatory Effects of Albendazole + Rad-Mil-28b Against Echinococcosis in Experiment-Infected Mice with Protoscoleces

An Echinococcus Multilocularis Antigen B3 Proteoform That Shows Specific Antibody Responses to Active-Stage Alveolar Echinococcosis

Current Status of Drug Therapy for Alveolar Echinococcosis

Ubenimex Combined with Albendazole for the Treatment of Echinococcus Multilocularis-Induced Alveolar Echinococcosis in Mice

Immunological Features and Efficacy of the Recombinant Subunit Vaccine LTB-EMY162 Against Echinococcus Multilocularis Metacestode

Biochemical Characterization of Echinococcus Multilocularis Antigen B3 Reveals Insight into Adaptation and Maintenance of Parasitic Homeostasis at the Host-Parasite Interface

Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis

The expression of CTLA-4 in hepatic alveolar echinococcosis patients and blocking CTLA-4 to reverse T cell exhaustion in Echinococcus multilocularis-infected mice

The Immunotherapy with Hmasp-2 DNA Nanolipoplexes Against Echinococcosis in Experimentally Protoscolex-Infected Mice.

Improvement of Antialveolar echinococcosis efficacy of novel Albendazole-Bile acids Derivatives with Enhanced Oral Bioavailability

A Bioengineered Nanovesicle Vaccine Boosts T‐B cell Interaction for Immunotherapy of Echinococcus multilocularis

Efficacy and Safety of Asparagusic Acid against Echinococcus multilocularis In Vitro and in a Murine Infection Model

In Vitro and in Vivo Efficacies of Carbazole Aminoalcohols in the Treatment of Alveolar Echinococcosis.

Immunization with EmCRT-Induced Protective Immunity Against Echinococcus Multilocularis Infection in BALB/c Mice

Albendazole in combination with artesunate to prevent the recurrence of cystic echinococcosis in mice

Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis